Showing 1,277 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Six questions about HIV/AIDS that deserve more attention

Editor's pick
Eurekalert Inf Dis
15 April 2015
New & experimental HIV treatments

Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

Editor's pick
ABIVAX press release
14 April 2015
The search for a cure

Editing HIV out of our genome with CRISPR

Editor's pick
University of Massacusetts Medical Schoool press release
13 April 2015
New & experimental HIV treatments

Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

Editor's pick
TAG
10 April 2015
New & experimental HIV treatments

In first human study, new antibody therapy shows promise in suppressing HIV infection

Editor's pick
Rockefeller University press release
9 April 2015
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Editor's pick
Gilead press release
8 April 2015
New & experimental HIV treatments

New lead against HIV could finally hobble the virus’s edge

Editor's pick
American Chemical Society
24 March 2015
New & experimental HIV treatments

HIV treatment: New inexpensive agents can block virus ability to replicate and develop resistance

Editor's pick
International Business Times
20 March 2015
New & experimental HIV treatments

Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks

News
19 March 2015
The search for a cure

Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Editor's pick
Seeking Alpha
10 March 2015
The search for a cure

We may need to combine many approaches to achieve a cure, delegates hear

News
9 March 2015
New & experimental HIV treatments

HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study

News
4 March 2015
HIV treatment

Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

News
27 February 2015
New & experimental HIV treatments

48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Editor's pick
Bristol Myers Squibb press release
26 February 2015
New & experimental HIV treatments

HIV maturation inhibitor BMS-955176 looks promising in early study

News
26 February 2015
The search for an HIV prevention vaccine

Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

Editor's pick
Huffington Post
19 February 2015
New & experimental HIV treatments

CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy

Editor's pick
CytoDyn press release
5 February 2015
Neurological & cognitive problems

Researchers identify key mechanisms underlying HIV-associated cognitive disorders

Editor's pick
Medical Xpress
4 February 2015
New & experimental HIV treatments

Treatment of the First HIV Positive Patient in ABIVAX's Phase IIa Clinical Trial With ABX464

Editor's pick
ABIVAX press release
2 February 2015
New & experimental HIV treatments

PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Editor's pick
Janssen press release
30 January 2015
New & experimental HIV treatments

U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Editor's pick
Bristol-Myers Squibb press release
30 January 2015
Pharmaceutical industry

Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

Editor's pick
Street Insider
26 January 2015
Resistance

Exploring possible treatment options after virological failure with raltegravir

Editor's pick
CATIE
21 January 2015
New & experimental HIV treatments

New anti HIV drug dolutegravir is effective at low doses

Editor's pick
MMD Newswire
21 January 2015